Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2009-02-17FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
FDA approved a supplemental application for Revatio (sildenafil citrate) submitted by Pfizer Laboratories Division, Pfizer Inc. The approval…
-
CLINICAL_TRIALS trial_result · 2008-10-17Clinical Trial Update: Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia [Phase 1]
Phase 1 trial evaluating safety and pharmacodynamic effects of bosentan (Tracleer) in patients with pulmonary arterial hypertension caused b…
-
FDA approval · 2008-09-12FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for REMODULIN (treprostinil) submitted by United Therapeutics Corporation.
-
CLINICAL_TRIALS research · 2008-07-02Clinical Trial Update: Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude [Phase 1]
Phase 1 trial evaluating whether iloprost affects hypoxic pulmonary vasoconstriction and exercise capacity at high altitude.
-
CLINICAL_TRIALS trial_result · 2008-06-30Clinical Trial Update: Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension [Phase 1]
A Phase 1 clinical trial evaluating a combination of spironolactone, captopril, and carvedilol for pulmonary arterial hypertension has compl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2008-06-27FDA Approved: VELETRI — Original Application (Actelion Pharmaceuticals US, Inc.)
FDA approved VELETRI (epoprostenol) from Actelion as an original application for treatment of pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2008-06-26Clinical Trial Update: Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. [Phase 4]
Phase 4 clinical trial evaluating long-acting phosphodiesterase-5 inhibitors as add-on therapy for patients with pulmonary arterial hyperten…
-
CLINICAL_TRIALS trial_result · 2008-05-07Clinical Trial Update: Bosentan in Treatment of Pulmonary Arterial Hypertension [Phase 4]
Phase 4 clinical trial update on bosentan for pulmonary arterial hypertension. The study involving Eisenmenger syndrome has completed.
-
CLINICAL_TRIALS research · 2008-04-08Clinical Trial Update: Rehabilitation for Patients With Pulmonary Arterial Hypertension [NA]
Clinical trial update describing a rehabilitation program for patients with pulmonary arterial hypertension, sponsored by Rabin Medical Cent…
-
FDA approval · 2008-02-25FDA Approved: SILDENAFIL CITRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental NDA for sildenafil citrate filed by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2008-02-21Clinical Trial Update: PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension [Phase 3]
Phase 3 PHIRST-1 trial evaluating tadalafil for pulmonary arterial hypertension has completed.
-
FDA approval · 2008-02-14FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, Inc. The approval involves changes to the p…
-
FDA approval · 2008-02-04FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
FDA approved a Supplemental Application for REMODULIN (treprostinil) by United Therapeutics Corporation. This action relates to an update or…
-
FDA approval · 2007-12-18FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Pfizer Laboratories Division Pfizer Inc.
-
FDA approval · 2007-11-29FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc. The action pertains to changes in …
-
CLINICAL_TRIALS trial_result · 2007-11-12Clinical Trial Update: Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction [Phase 4]
Phase 4 study evaluating safety, efficacy and treatment satisfaction when transitioning PAH patients from Ventavis (iloprost) to IV Remoduli…
-
CLINICAL_TRIALS trial_result · 2007-11-09Clinical Trial Update: Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension [Phase 3]
Clinical trial update announcing the completion of a Phase 3 safety and efficacy study of sitaxentan (Thelin) in pulmonary arterial hyperten…
-
FDA approval · 2007-10-18FDA Approved: SILDENAFIL CITRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for sildenafil citrate from Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2007-10-16Clinical Trial Update: Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?
A clinical trial update examining whether intravascular hemolysis occurs in patients with pulmonary arterial hypertension.
-
CLINICAL_TRIALS withdrawal · 2007-08-30Clinical Trial Update: Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension [Phase 2]
Phase 2 dose-determination safety and activity study of inhaled NX1011 for pulmonary arterial hypertension has been withdrawn.
-
FDA approval · 2007-06-15FDA Approved: LETAIRIS — Original Application (Gilead Sciences, Inc.)
The FDA approves LETAIRIS (ambrisentan) in an original application from Gilead Sciences for the treatment of pulmonary arterial hypertension…
-
CLINICAL_TRIALS trial_result · 2007-06-07Clinical Trial Update: Hemodynamic Response After Six Months of Sildenafil [Phase 4]
This document provides an update on a Phase 4 clinical trial of sildenafil for pulmonary arterial hypertension. It focuses on hemodynamic re…
-
FDA approval · 2007-06-01FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) filed by Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2007-02-15FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, Inc., updating the product's labeling as p…
-
FDA approval · 2006-07-27FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
The FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Pfizer Laboratories Div Pfizer Inc.